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Abstract
Background: Minor histocompatibility antigens (mHA) mediate much of the graft vs. leukemia (GvL) effect and graft vs. host
disease (GvHD) in patients who undergo allogeneic stem cell transplantation (SCT) [1,2,3,4]. Therapeutic decision making
and treatments [5] based upon mHAs will require the evaluation of multiple candidate mHAs and the selection of those with
the potential to have the greatest impact on clinical outcomes. We hypothesized that common, immunodominant mHAs,
which are presented by HLA-A, B, and C molecules, can mediate clinically significant GvL and/or GvHD, and that these mHAs
can be identified through association of genomic data with clinical outcomes.
Methodology/Principal Findings: Because most mHAs result from donor/recipient cSNP disparities, we genotyped 57
myeloid leukemia patients and their donors at 13,917 cSNPs [6]. We correlated the frequency of genetically predicted mHA
disparities with clinical evidence of an immune response and then computationally screened all peptides mapping to the
highly associated cSNPs for their ability to bind to HLA molecules. As proof-of-concept, we analyzed one predicted antigen,
T4A, whose mHA mismatch trended towards improved overall and disease free survival in our cohort. T4A mHA mismatches
occurred at the maximum theoretical frequency for any given SCT. T4A-specific CD8+ T lymphocytes (CTLs) were detected
in 3 of 4 evaluable post-transplant patients predicted to have a T4A mismatch.
Conclusions/Significance: Our method is the first to combine clinical outcomes data with genomics and bioinformatics
methods to predict and confirm a mHA. Refinement of this method should enable the discovery of clinically relevant mHAs
in the majority of transplant patients and possibly lead to novel immunotherapeutics [5].
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Introduction
Allogeneic stem cell transplant (SCT) is curative for many
patients with advanced hematologic malignancies, and in recent
years, the role of donor-derived immunity (i.e. GvL) has been
shown to be crucial in maintaining durable remissions [7,8,9,10].
One strong piece of evidence to support the role of donor-derived
immunity in the setting of SCT is the 20-year old observation that
syngeneic SCT is associated with 3-fold higher rates of relapse
when compared to HLA-matched allogeneic SCT [2].
The fact that syngeneic SCT has a higher relapse rate compared
to HLA-matched, allogeneic SCT [2], and that this increased
relapse rate rivals that of HLA-matched allogeneic SCT with
donor T cell depletion [4], is indirect evidence that much of the
clinically observed GvL effect is mediated by donor T cell
reactivity against patient mHAs (presented on HLA-A, B, C
molecules) that differ in peptide sequence from the homologous
mHAs present in the donor [1,6]. These peptide differences
between donor and patient that may account for the curative GvL
are often the result of non-synonymous coding single nucleotide
polymorphisms (cSNPs) that yield a protein with a single amino
acid difference between the donor and patient [1,6]. Donor T cells
obtained from a donor who is homozygous for a certain allele in a
given HLA epitope would be predicted to be intolerant towards an
HLA epitope derived from the alternate allele. In such cases,
donor T cells would be predicted to mount an immune response
upon exposure to the alternate allele epitope if it is expressed by
the patient. This mechanism of allo-immunity has been confirmed
in several well-characterized mHAs such as HA-1 and LB-ADIR-
1F [3,11,12].
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ment of a donor-derived T cell clone obtained from the patient
post-SCT that reacts to an unknown antigen expressed on an
antigen presenting cell usually, but not always, obtained from the
recipient [5,13,14,15,16,17]. These cloning approaches, by
themselves, are unable to provide immediate information
regarding the minor antigen’s HLA-restriction, chemical structure,
tissue restriction or allele frequency – characteristics that are
important considerations if mHA therapeutics are to be developed
clinically. Determination of these properties requires further
experimentation that can only be performed after the initial
cloning [12,18]. Because each SCT has thousands of potential
mHA mismatches: some unique to that particular donor patient
pair and others common in multiple transplant pairs, each with
varying levels of immunogenicity, the individual characterization
of T cell clones is insufficient to screen all of the potential mHA in
the human population. If therapeutic decision-making that is
based on minor histocompatibility antigen analysis is to become
part of standard clinical practice, methods must be developed to
efficiently evaluate multiple candidate mHAs and determine which
ones have the properties (e.g. antigen frequency, tissue expression,
association with clinical outcomes) most likely to provide the
greatest impact on clinical outcomes for large patient cohorts
[3,19,20]. With the advent of robust high-throughput genomic
platforms, cSNP analysis of patient populations is being performed
in many diverse fields, and should be applicable to mHA discovery
[14,15,21]. Given the large size and genetic diversity throughout
the human population, the number of allelic mismatches occurring
between any given HLA-identical donor/patient pair is prohib-
itively large to perform a detailed characterization of each
potential mHA mismatch and its resulting capacity to generate
an immune response [22]; however, we hypothesized that
common, immunodominant mHAs that mediate clinically signif-
icant effects can be discovered by analyzing clinical outcomes from
a cohort of SCT patients, correlating the clinical outcomes with
genetically predicted mHA mismatches, and using bioinformatics
platforms to simplify the identification of the actual HLA epitopes.
To test our hypothesis, we applied this general approach to a
SCT patient cohort with the aim of identifying a common,
immunodominant mHA. In this pilot study, we evaluated 13,917
cSNPs and measured the association between donor/recipient
cSNP disparities and recipient outcomes. In a cohort of 57
myeloid leukemia patients, we identified a new common mHA,
T4A, which was associated with a trend toward improved OS,
DFS, and relapse rate. T4A immunogenicity was confirmed by
identifying functional CD8+ T cells in post-SCT patients.
Additionally, T4A possesses several properties that make it a
good target mHA: 1) T4A mHA mismatch occurs at the
theoretical maximum frequency for any given SCT population
and 2) T4A expression is highly restricted to hematopoietic tissue
and leukemia.
Materials and Methods
Patient Cohort Assembly
Written informed consent for blood sample collection was
obtained from all patients and donors through an M.D. Anderson
IRB-approved protocol (LAB99-062). Research was conducted
according to the principles in the Declaration of Helsinki. We
initially attempted to create a large patient cohort consisting of
HLA-A2+ patients with myeloid leukemia (AML, CML, MDS)
who had undergone an HLA-matched related HSCT and had not
developed a GvHD beyond either acute GvHD (aGvHD) grade 1
or limited chronic GvHD (cGvHD). We were unable to obtain a
sufficiently large number of samples using these criteria so we
decided to add myeloid leukemia patients who had developed
either aGvHD . grade 1 or extensive cGvHD. The addition of
these patients increased our test cohort from 36 to 57 patients. We
obtained paired pre-transplant donor and patient peripheral blood
mononuclear cells (PBMC) from the tissue bank of the
Department of Stem Cell Transplantation and Cellular Therapy
under an IRB approved protocol. For 9 of the 57 samples we used
post-transplant, 100% donor chimeric PBMC samples as the
‘‘donor sample’’. We extracted genomic DNA from the frozen
PBMC samples using QIAamp (Qiagen, Valencia, CA) Blood
DNA extraction kits according to the manufacturer’s instructions.
Donor/Patient Genotyping
Genomic DNA from the 57 patients and their matched donors
was analyzed at 13,917 well-annotated cSNPs using Illumina NS-
12 microarrays. This analysis was performed at the University of
Texas at Houston School of Medicine microarray core facility.
Peptide synthesis
Candidate peptides were synthesized by the M.D. Anderson
peptide core facility using traditional f-moc chemistry, and
peptides for the iTopia Epitope Discovery System were synthe-
sized by Bioynthesis (Lewisville, TX). All peptides were purified by
HPLC, and molecular weights were confirmed by mass spectrom-
etry.
Epitope binding assays
Peptides were dissolved in DMSO and diluted with milli-Q
water to reach a stock concentration of 1 mM peptide with 1%
DMSO. TAP deficient T2 cells were incubated in complete media
(CM) consisting of RPMI supplemented with 10% FBS and 1%
penicillin/streptomycin (P/S) at a concentration of 1610
6 cells/
mL and a viability of .90%. The cells were then washed 3 times
in serum-free RPMI with 1% P/S and resuspended at a
concentration of 1610
6 cell/mL. Candidate epitope peptides
were added to make a final concentration of 100 mM peptide.
The T2 cells were incubated for 18 h in 5% CO2 at 37 uC. After
incubation, T2 cells were washed in sterile phosphate buffered
saline (PBS) twice and incubated with unconjugated BB7.2
antibody (10 mL purified hybridoma supernatant) for 30 min at
4uC. The cells were washed with sterile PBS once and then
incubated for 15 min at 4uC with 5 mL FITC-labeled goat anti-
mouse IgG antibody (Caltag, Burlingame, CA). Mean fluorescence
intensity in the FITC channel was measured for live T2 cells in all
samples. All assays were performed with a no-peptide control and
a mM PR1 (VLQELNVTV) peptide loaded positive control.
Additional characterization of the P12 peptide (renamed T4A)
binding to HLA-A0201 was performed using the iTopia Epitope
Discovery System (Beckman Coulter, Miami, FL), following the
manufacturer’s protocol. To determine the ability of the T4A and
T4E (the alternate allele) peptides to bind HLA-A0201, peptides
were incubated in duplicate in HLA-A0201 coated wells at a
concentration of 11 mMa t2 1 uC overnight, and% peptide binding
was calculated relative to the positive control peptide
(FLPSDFFPSV). Per the manufacturer, peptides binding $30%
of the positive control are candidate HLA-A0201 epitopes. To
measure T4A binding affinity, the T4A peptide and control
peptide were incubated in separate HLA-coated wells at peptide
concentrations ranging from 10
24 to 10
28 Ma t2 1 uC overnight.
Results from duplicate wells were graphed relative to the positive
control peptide, and the ED50 was determined using GraphPad
Prism’s nonlinear regression, ‘log (agonist) versus response –
variable slope (four parameter)’ curve. For off-rate analysis, T4A
Genomic Based Minor Antigen Discovery
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coated wells at a concentration of 11 mMa t2 1 uC overnight, then
washed and incubated at 37uC and read over the course of 8 hrs.
Results from duplicate wells were graphed relative to the positive
control peptide as 100% binding at each time point. The t1/2 was
calculated using GraphPad Prism’s nonlinear regression, ‘dissoci-
ation – one phase exponential decay’ curve.
Tetramer Synthesis and Flow Cytometry
Tetramers were made, in our laboratory, for all of the peptides
that bound HLA-A2 using the T2 binding assay according to
published protocols [23]. Briefly, peptide loaded monomers were
made in a 100 mL reaction consisting of 1 mg HLA-A0201
monomer containing a biotinylation recognition site, b2-micro-
globulin, and 1–2 mg of the peptide. After 3 days of incubation at
4 uC, the monomers were purified by size-exclusion chromatog-
raphy on a Pharmacia FPLC and subsequently biotinylated using
BirA ligase. The biotinylated monomers were purified by ion-
exchange chromatography, and tested for purity by SDS-PAGE.
Monomers were then reacted with phycoerythrin (PE) conjugated
streptavidin and subsequently purified on 100 kDa membranes to
yield PE-conjugated tetramers.
Frozen post-transplant PBMC patient samples were thawed and
washed once in CM and once in PBS. Cell counting and viability
was performed, and approximately 1610
6 cells (when possible)
were incubated with 2 mL each of PE-Cy5-conjugated CD4,
CD14, CD16, CD19 antibodies (‘dump’ channel), 1 mL FITC-
conjugated CD8 antibody (all antibodies Caltag, Burlingame, CA),
and 2.5 mg PE-conjugated tetramer at 4uC for 30 mins. Two mL
aqua live/dead stain (Invitrogen, Carlsbad, CA) were added
25 mins into the labeling procedure. Single stain controls were
used for compensation purposes. Samples were washed once after
incubation and analyzed immediately on a Cyan flow cytometer.
Tetramer+ cells were enumerated in the live (aqua-), lymphocyte
(FS/SS), CD8+, ‘dump’2 gate.
Cytokine secretion assay
Normal donor buffy coats that served as negative controls were
purified by ficol-hypaque purification and tested for HLA-A2
expression using BB7.2 antibody with a FITC-labeled antimouse
IgG secondary antibody. Each HLA-A2+ buffy coat was
genotyped at the rs9876490 (ref. seq. for the T4A peptide) SNP.
1610
6 PBMC from an HLA-A2+ buffy coat containing an AC
genotype (predicted to be tolerant to the T4A peptide) and a ficol-
hypaque sample obtained from the T4A gIR+ post-SCT evaluated
in Figure 3C were incubated for 6h with 1610
6 T4A pulsed T2
cells, unpulsed T2 cells, or 2 mL OKT3 antibody. Each sample
was incubated in 1 well of a 96 well plate containing 200 mLo f
CM. After 6 h supernatant was removed, and submitted for
Luminex analysis measuring IFN-c and TNF-a secretion.
Tetramer-Cytokine Flow Cytometry
B lymphocytes from healthy donors expressing HLA-A0201
were immortalized using Epstein-Barr virus infection to generate
EBV-LCLs. TRIM42 protein expression in each LCL was
confirmed by western blot. Genomic DNA was isolated from
each EBV-LCL, and PCR was used to amplify DNA flanking the
T4A associated cSNP (rs9876490). Conventional Sanger sequenc-
ing was performed to determine the genotype at rs9876490 for
each EBV-LCL. One EBV-LCL line had a genotype predicted to
produce T4A peptide (T4A+), and another EBV-LCL had a
genotype predicted to only produce the alternate peptide (T4A2).
An HLA-A2/T4A-APC tetramer was synthesized in our
laboratory as described above. Frozen PBMC samples from
post-SCT, T4A gIR+, patients were thawed, and 2.5 mgo f
tetramer were added to 1610
6 PBMC and incubated for 30 min
on ice in the dark. The PBMC were washed in PBS and
resuspended in CM. Tetramer stained PBMC were incubated with
1610
6 T4A+ or T4A- EBV-LCLs in a 1:1 ratio in a well of a v-
bottom 96-well plate. To each well was added 2 mL pure CD28
and 0.5 mL pure CD49d. The PBMC/EBV-LCL cultures were
incubated for 1 hr at 37uCi n5 %C O 2, and then brefeldin A was
added. The cells were incubated for an additional 5 hrs and then
transferred to 4uC overnight. Media was removed and the cells
were incubated in PBS +0.02% EDTA at 37uC for 10 min, then
washed in PBS. Cells were stained with Live/Dead Fixable Aqua
(Invitrogen, Carlsbad, CA) for 20 min on ice. Cells were then
washed with PBS and resuspended in FACS Lyse (Beckton
Dickinson, Franklin Lakes, NJ) solution for 10 mins at room
temperature. Following this, the cells were again washed and
resuspended in FACS PermII (Beckton Dickinson) solution for
10 mins at room temperature. The cells were washed once in PBS
+1% BSA +0.02% sodium azide. The following fluorescently
conjugated antibodies were added to each sample: 4 mL CD8-
APC-H7 (Beckton Dickinson); 2 mL each CD4, CD14, CD16-
Pacific Blue (Beckton Dickinson), CD19-Pacific Blue (Biolegend,
San Diego, CA); 4 mL IFN-c-PE-Cy7 (Becton Dickinson); 1 mL
Aqua Live/Dead (Invitrogen). The cells were incubated for
30 mins at 4uC, and were then washed once in PBS +1% BSA
+0.02% sodium azide. The cells were fixed in 200 mLo f1 %
paraformaldehyde and analyzed using a BD LSRII Fortessa flow-
cytometer. Tetramer+, IFN-c+ cells were enumerated in the live
(aqua-), lymphocyte (FS/SS), CD8+, ‘dump’2 gate.
Survival Analysis
OS, DFS and relapse rates for the T4A gIR+ and T4A gIR-
groups in the 57 patient cohort were analyzed using Kaplan-Meier
survival curves [24]. Survival differences were compared using the
log-rank test.
Western Blot Analysis
Normal human tissue lysates (heart, testis, colon, skin, liver)
prepared using RIPA buffer and SDS sample buffer were
purchased from Prosci (Poway, CA). Four human AML samples,
a PBMC sample and a Jurkat cell lysate were also prepared using
RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% sodium
deoxycholate, 1 mM EDTA, 0.1% SDS, 1% Triton-X and
Sigmafast Protease Inhibitor (Sigma-Aldrich, St. Louis, MO).
Twenty mg of each lysate (Micro BCA protein assay, Thermo
Scientific, Rockford, IL) were incubated with loading dye (2%
SDS, 10% glycerol, 62.5 mM Tris, pH 6.8, 5% beta-mercapto-
ethanol and 0.002% bromophenol blue) in a total volume of 15 mL
for 5 min at 98uC. Each sample was loaded onto a 4–12%
NuPAGE gradient gel (Invitrogen, Carlsbad, CA) and electropho-
resed at 100 mV for 140 min. The gel was then transferred to a
PVDF membrane using a Mini-PROTEAN Trans-Blot Module
(Biorad, Hercules, CA) at 250 mA for 70 min and blocked with
5% milk for 1 hr prior to incubation with the anti-TRIM42
antibody (Abcam, Cambridge, MA) at 1:1000 dilution overnight at
4uC. The next day, the membrane was washed for 30 min in TBS-
0.1% Tween and then incubated with horse-radish peroxidase
conjugated anti-rabbit IgG antibody for 1 hr and developed using
the Amersham ECL Western Blotting Detection kit (GE
Healthcare, Piscataway, NJ). The membrane was reprobed with
monoclonal anti-GADPH antibody (Sigma-Aldrich, St. Louis,
MO).
Subcellular fractionation of AML blasts and normal granulo-
cytes was performed using Proteoextract subcellular fractionation
Genomic Based Minor Antigen Discovery
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(Bradford assay) were incubated with 6 mL beta-mercaptoethanol
and 50 mM DTT in a total volume of 20 mL for 10 min at 100
uC. Each sample was loaded onto a 5–15% SDS-PAGE gradient
gel (Biorad, Hercules, CA) and electrophoresed at 100 mV for
90 min. The gel was then transferred to a PME membrane using
an electric gel blotter at 15 mV for 50 min and blocked with 2.5%
milk for 1 hr. The membranes we then developed as described
above.
Results
Patient characteristics
Table 1 shows the clinical characteristics of the 57 patient
cohort. Following preliminary selection based upon database
records of HLAA2+ type, disease, remission status and GvHD
status we performed a more thorough chart review of all of the
patients. From this review we found that 2 patients who had been
classified as 10/10 HLA-match actually underwent HSCT from a
related, but 1-antigen mismatch donor. Neither of these
mismatches occurred in the HLA-A locus. The rates of acute
and chronic GvHD in the cohort were lower than would be
expected in a typical transplant cohort [25]; however, the lower
GvHD incidence is a result of our initial attempts to capture only
myeloid HLA-A2+ patients who did not have GvHD.
Association of cSNP mHA disparities with clinical
outcomes
Figure 1 shows a schematic of how candidate cSNP alleles were
identified as potential mediators of clinically significant immune
responses. The 57 patients were clinically classified according to
remission status and GvHD as described in Materials and
Methods and represented in Figure 1A. The 4 subgroups can be
considered to represent 2 broad clinical outcomes patients with
evidence of a clinical immune response (cIR+, blue boxes), and
patients without evidence of a clinical immune response (cIR-,
unshaded box). Genomic DNA from each patient and his/her
donor was genotyped at 13,917 cSNPs using Illumina NS-12
microarrays, and disparities between the donor and recipient pair
were evaluated as illustrated in Figure 1B. For each cSNP a
disparity involving a homozygous donor and genetically noniden-
tical (i.e. heterozygous at that cSNP or homozygous for the
alternate allele) recipient was scored as genetically predictive of an
immune response (gIR+, red boxes). All other genetic combina-
tions were scored as genetically predictive of no immune response
(gIR-, unshaded boxes). Each cSNP allele was evaluated by scoring
the number of gIR+ and gIR- pairs in the entire patient cohort.
Fisher’s exact test was then applied for each cSNP to measure the
association of gIR+ with cIR+ (Figure 1C). A strong association
(i.e. low P-value) would be expected to occur if a cSNP allele
yielded a large number of gIR+ disparities, and the gIR+
disparities preferentially occurred in the cIR+ group (Figure 1C),
purple box. From the 57 patients in our test cohort we measured
the association of cSNP gIR with cIR for 27,834 (13,917 cSNPs
62 alleles/cSNP) alleles. The resultant list was ranked by P-value
with the allele having the strongest association (rs2273959_T)
between gIR and cIR having a P-value of 0.019 (Table 2). The 40
cSNPs that yielded the lowest P-value were further characterized
in this pilot study.
Bioinformatic methods accelerate candidate epitope
discovery
Because of the large number of cSNPs tested the problem of false-
positive results from multiple testing is significant in our method. To
address this concern, we evaluated the 40 cSNPs with gIR+ most
strongly associated with a cIR+ as possible mHAs by first using the
Ensembl (www.ensembl.org) database, to map the cSNPs to a
known peptide sequence (19 amino acids in length with the cSNP
associated amino acid at position 10) that contained allelic
variations resulting in an amino acid change. From the 40 cSNPs
16 were removed at this step because they could not be mapped to a
known protein sequence with the given allelic variation. For the
remaining 24 cSNPs, all 9 and 10 amino acid peptides that
contained the cSNP allele that would encode the predicted recipient
peptide were tested for possible binding to HLA-A0201 using the
IEDB SMM algorithm (www.immuneepitope.org) [26] and the
SYFPEITHI (www.syfpeithi.org) [27] algorithm. Any cSNP with an
associated peptide that reached our loose binding criteria (IEDB
IC50,1,000 nM or SYFPEITHI score $17) was selected as a
potential HLA-A2 epitope and possible mHA. From the 24 cSNPs,
we identified 15 that had at least 1 candidate HLA-A2 restricted
epitope according to IEDB or SYFPEITHI. From the 15 identified
cSNPs, we ordered 23 peptides with 17 subsequently being made at
high purity (Table 2). Two of the 23 ordered peptides, P6 and P20
Table 1. Patient cohort characteristics.
Characteristics Patients, N=57 (%)
Median Age, years (range) 48 (21–66)
Gender
Male patient 37 (65)
SMM =20 (54)
Female patient 20 (35)
SMM =9 (45)
Disease (%)
AML 29 (51)
CR =14 (48)
CML 17 (30)
CP =12 (71)
MDS 11 (19)
CR =0 (0)
Cytogenetics
Favorable 16 (28)
Not favorable 41 (72)
Conditioning
Myeloablative 44 (77)
Reduced intensity 13 (23)
Donor source
Bone Marrow 9 (16)
Peripheral blood stem cell 48 (84)
Donor type
HLA-matched 55 (96)
1 antigen mis-matched 2 (4)
Patient or Donor CMV+ 49 (86)
GvHD Incidence
Acute $ grade 2 14 (25)
Extensive chronic 11 (19)
SMM denotes a sex mismatched transplant.
CR denotes complete remission at the time of transplant.
CP denotes chronic phase at the time of transplant.
doi:10.1371/journal.pone.0023217.t001
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to further assess the binding algorithms’ performance characteris-
tics. Six of the 23 peptides that were ordered could not be
synthesized efficiently because of their hydrophobicity and the
resulting difficulty with purification.
Using a T2 cell-based binding assay as a screening test for peptide-
HLA binding, we considered any peptides that induced a geometric-
mean fluorescenceshift.1.56the unpulsed control to have evidence
of HLA-A2 binding in-vitro. Five of the 17 tested peptides bound
HLA-A0201 according to our assay (Figure 2A– 2E). Figure 2F shows
a representative binding assay of one of the peptides that did not bind
HLAA0201 according to our assay. In evaluating our in-silico
prediction analysis we observed that all peptides predicted to have
a dissociation constant of ,5 0 0n Mb yt h eI E D BS M Ma l g o r i t h m
bound HLA-A0201 in our assay conditions, whereas the SYPEITHI
algorithm was not predictive in our hands (Table 2).
Evidence of T4A-specific CD8+ T cell expansion in post-
SCT samples
To look for evidence of candidate mHA-specific T lymphocyte
activity, we first synthesized PE-conjugated/HLA-A0201 tetramers
for each of the 5 binding peptides shown in Figure 2. We then
performed tetramer analysis on posttransplant PBMC samples that
were $3 months post-transplant, and were predicted to have a
gIR+ to one of the predicted mHA. For the 5 tetramers analyzed we
identified between 2 and 5 samples that met our criteria. For
peptides 8 and 9 (derived from the same cSNP) we tested 4 gIR+
samples and found no tetramer specific responses. For peptide 13
we tested 2 gIR+ samples and found no tetramer-specific responses,
andforpeptide18wetested3 gIR+ samplesand found notetramer-
specific responses. We identified 5 post-SCT samples that had gIR+
to the 12
th peptide synthesized (P12, GLYTYWSAGA); however, 1
of these samples had poor viability and could not be analyzed by
flow cytometry. In 3 of the remaining 4 samples examined we
identified distinct tetramer+ populations in the live, CD8+,
‘dump’2 gate (Figure 3A– C). The sample that did not have a
tetramer+ population was obtained from a patient 9 months post-
transplant who was on systemic steroids for extensive cGvHD
(Figure 3D). We did not identify any tetramer+ populations in an
HLA-A2- control (Figure 3E), or 2 HLA-A2+, 3-month post-
transplant samples from patients genetically predicted to be gIR- to
GLYTYWSAGA (Figure 3F, 3G). The P12 peptide, renamed T4A,
is derived from the alanine allele on cSNP rs9876490_C, which is
contained in the protein TRIM42.
Figure 1. Schematic of mHA selection method. All 57 patients were classified by GvHD and remission status (1A). The patients in the remission,
GvHD+; remission, GvHD-; and relapse, GvHD+ groups were considered as the clinical immune response cohort (cIR+, blue shaded boxes), and the
relapse, GvHD- group was considered the clinical non-immune responder group (cIR-, unshaded box). All potential allele combinations for any cSNP
in the setting of allogeneic SCT can be represented by a 363 table( 1B). Given a major allele ‘A’ and minor allele ‘a’ at any particular cSNP locus, then a
donor (D) may be homozygous for the major allele (AA, genotype frequency = p
2), heterozygous (Aa, genotype frequency =2pq), or homozygous
for the minor allele (aa, genotype frequency = q
2). The same assignments can be made for the recipient (R). Assuming potential minor
histocompatibility antigens arise from non-synonymous cSNPs, then the genotype frequencies can be multiplied to give the predicted frequencies of
a donor/recipient immune reaction against peptide antigens encoded by that locus. For a donor that is homozygous at a given cSNP, 3 potential
immune responses can be predicted based on the genotype of the recipient: 1) tolerance, 2) non-tolerance in the GvL/GvHD direction, and 3) non-
tolerance in both the GvL/GvHD and rejection directions. Scenarios 2 and 3 are defined as genetically predictive of an immune response (gIR+, red
shaded boxes). No gIR is predicted if a donor is heterozygous at a given locus or if the donor and recipient share the same genotype (gIR-, unshaded
boxes). The association between gIR+ and cIR+ for each allele in each cSNP was determined using Fisher’s exact test (1C).
doi:10.1371/journal.pone.0023217.g001
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After T4A-specific responses were observed in post-SCT
samples we further characterized T4A’s binding properties. The
T4A peptide binds HLA-A0201 with high affinity when compared
to a positive control peptide; however, the analogous peptide
encoded by the alternate allele, rs9876490_A, (T4E = GLY-
TYWSAGE) did not bind HLA-A0201 (Figure 4A). This finding is
consistent with a minor antigen mismatch as donors who are
homozygous for rs9876490_A and are only capable of producing
T4E will be intolerant to T4A because their T lymphocyte
repertoire will not have been exposed to the GLYTYWSAG motif
because the C-terminal glutamate residue prevents proper binding
to HLA-A0201. T4A’s ED50 is 1.3 mM, and the dissociation half
time, t1/2, is 1.00 hr (Figure 4B, 4C).
Because of concerns about immune-mediated toxicity from
mHA-specific CTLs towards non-hematopoietic tissues, we
evaluated TRIM42 tissue expression. We performed western blots
to probe for TRIM42 protein in normal human tissues and AML
samples (Figure 4D). Western blotting for TRIM42 in Jurkat cells,
a positive control, revealed two bands of roughly 100 kDa and
50 kDa. The high MW band is identified as TRIM42 (Abcam
reference western blot performed on Jurkat cells), but the identity
of the low MW band is unknown. We probed for TRIM42 in 5
human tissues, colon, heart, skin, liver, testis, and 4 human AML
samples (Figure 4D). We observed varying amounts of TRIM42
protein in all 4 AML samples, but were not able to detect
appreciable amounts of TRIM42 in our human tissues, which
included the 3 main target organs for GvHD, colon, skin and liver.
We subsequently created subcellular fractions of AML blasts and
normal granulocytes to determine the localization of TRIM42 in
AML. We could not identify any TRIM42 specific bands in the
normal granulocyte subcellular fractions. However, we did observe
the same 2 bands identified in our previous western blots in the
nuclear and cytoskeletal fractions of the AML sample (Figure 5E).
The significance of the low molecular weight band being found
without the high molecular weight band in the AML membrane
fraction is not known. Some TRIM proteins, including PML/
TRIM19, are involved in transcriptional regulation [28,29], while
others such as TRIM25 are involved in innate immunity and anti-
viral responses [30,31,32]. The function of TRIM42 is not known.
For mHAs to be of clinical utility in a SCT population they
must occur at a frequency that is high enough to justify their
development as a therapeutic. The TRIM42 cSNP, rs9876490,
identified in our study has been annotated through the Human
Table 2. Peptides selected for evaluation.
Name Recipient Allele P-value Gene Peptide IEDB SY. Donor allele Donor peptide
*P1 rs2273959_T 0.019 SDCBP2 ASGDKIVMVV 642 17 rs2273959_C ASGDKIVVVV
P2 rs2273959_C 0.019 SDCBP2 ASGDKIVVVV 1458 19 rs2273959_T ASGDKIVMVV
*P3 rs4984906_A 0.021 WDR90 FLWDVLATT 639 25 rs4984906_A FLWDVLAPT
*P4 rs4479748_C 0.023 ENPP6 CMLKGRAGT 3303 19 rs4479748_C CMLKGRAST
P5 rs1801262_T 0.024 NEUROD1 TMNAEEDSL 860 21 rs1801262_T AMNAEEDSL
P6 rs1864346_T 0.024 OR6N1 QVTEFIILG 2159 10 rs1864346_T QVAEFIILG
P7 rs1864346_T 0.024 OR6N1 SQVTEFIILG 718 6 rs1864346_T SQVAEFIILG
P8 rs1551122_A 0.025 C12orf64 IAMFANNWSV 49 18 rs1551122_A IAMFANSWSV
P9 rs1551122_A 0.025 C12orf64 AMFANNWSV 394 23 rs1551122_A AMFANSWSV
*P10 rs2303771_A 0.042 KLHDC4 LYNELYVYNI 2458 18 rs2303771_A LYNELYVYNT
P11 rs2303771_A 0.042 KLHDC4 NIRKDTWTKV 847 20 rs2303771_A NTRKDTWTKV
P12 rs9876490_C 0.043 TRIM42 GLYTYWSAGA 226 19 rs9876490_C GLYTYWSAGE
P13 rs3748816_G 0.043 MMEL1 YILEETNRRL 248 24 rs3748816_G YILEEMNRRL
P14 rs3748816_G 0.043 MMEL1 ILEETNRRL 2792 23 rs3748816_G ILEEMNRRL
P15 rs9373475_T 0.044 FBOXO30 DLGDMKNDV 1308 22 rs9373475_T DLGDVKNDV
P16 rs11649804_A 0.045 RAI1 VTFRTHSLHV 508 17 rs11649804_A VPFRTHSLHV
P17 rs11649804_A 0.045 RAI1 QVTFRTHSL 2248 17 rs11649804_A QVPFRTHSL
P18 rs214976_A 0.046 SYNE1 FLASVEECRT 333 17 rs214976_A FLASVEECRT
P19 rs214976_A 0.046 SYNE1 SVEECRTEL 8780 19 rs214976_A SAEECRTEL
P20 rs214976_A 0.046 SYNE1 SVEECRTELD 52688 7 rs214976_A SAEECRTELD
*P21 rs1049534_T 0.046 THOC5 SIPPIFQLCL 3985 23 rs1049534_T SIPPVFQLCL
P22 rs11567842_G 0.047 SLC13A2 IIGVLIVALA 1494 20 rs11567842_G IIGVLIIALA
P23 rs11567842_G 0.047 SLC13A2 IIGVLIVAL 556 28 rs11567842_G IIGVLIIAL
*Denotes peptides that could not be synthesized at high purity.
IEDB = IEDB SMM predicted IC50 (nM).
SY. = SYFPEITHI algorithm binding score.
The cSNP alleles with the strongest association between gIR+ and cIR+ in the 57-patient cohort are shown. For each cSNP, gIR analysis was performed twice, once with
the major allele considered the recipient allele (i.e. the allele that encodes the peptide presented by the recipient that is recognized by the donor T lymphocyte
repertoire) and once with the minor allele considered the recipient allele. The cSNPs are ranked by decreasing statistical association of gIR+ and cIR+ for the recipient
allele (column 2). The peptide containing the recipient allele-associated amino acid (shown in bold) that was predicted to bind most tightly to HLA-A0201 according the
IEDB (SMM) and SYFPEITHI algorithms are shown in column 5 with IEDB and SYFPEITHI prediction scores in columns 6 and 7 respectively. The corresponding donor
allele and donor peptide (i.e. the peptide associated with the donor’s homozygous allele are shown in columns 8 and 9 respectively.
doi:10.1371/journal.pone.0023217.t002
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23217Figure 2. Peptide binding to HLA-A2. All synthesized peptides from Table 2- were tested for binding to HLAA2 using a T2 cell binding assay.
Unpulsed T2 cells are shown as shaded traces. Test peptide-pulsed T2 cells are shown as traces with dashed lines, and PR1-pulsed T2 cells are shown
as solid black lines. The PR1 peptide was used as a positive control because it binds HLA-A2 with high affinity. Five of 17 peptides bound to HLA-A2
with an increase in geometric mean fluorescence of .1.5 fold compared to the non-pulsed control (2A–2E). A representative non-binding peptide is
shown (2F).
doi:10.1371/journal.pone.0023217.g002
Figure 3. T4A-specific CD8+ T cell expansion in post-SCT patient samples. T4A-specific CD8+ T cells are detected in post-transplant samples
using T4A loaded, HLA-A2/PE conjugated tetramers. Of four patients with gIR+ to the cSNP at position rs9876490_C with available post-SCT PBMC
samples, T4A-tetramer+ CD8+ lymphocytes were identified in 3 patients (3A–3C). The fourth patient with no detectable T4A-specific T lymphocytes
was receiving systemic steroids for extensive cGvHD (3D). No T4A/HLA-A2 tetramer+ cells were detected in a control HLA-A2 negative recipient (3E),
or in two HLA-A2+ post-transplant T4A gIR- patients (3F, 3G). The mean percentage of T4A-tetramer+ cells in the CD8+ population in samples 3A, 3B,
and 3C was 0.07360.015% compared to 0.02160.001% for samples 3E, 3F, 3G (student t-test, P=0.0278).
doi:10.1371/journal.pone.0023217.g003
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23217Figure 4. T4A binding, tissue expression, and antigen frequency. The iTopia epitope binding assay was used to measure T4A and the
alternately encoded T4E peptide (GLYTYWSAGE) binding to HLA-A2 compared to the percentage of maximal binding of the iTopia control peptide
(FLPSDFFPSV). T4A binding to HLA-A0201 is 95% of that compared to the positive control; however, T4E binds HLA-A0201 at 24% that of the positive
control. According to the manufacturer, peptides binding of .30% that of the control peptide are candidate HLA-A0201 epitopes (4A). The iTopia
assay was also used to measure the ED50 and dissociation t1/2 of T4A to HLA-A2 relative to the iTopia positive control (FLPSDFFPSV) labeled ‘‘POS’’.
T4A binds with a 50% effective dose of ED50=1.3 mM and a dissociation half time of t1/2=1.00 hr (4B, 4C). Western blots on whole cell lysates of
normal human tissue (colon, heart, liver, skin, testis and PBMC), 4 human AML samples and Jurkat cells (positive control) are shown (4D). Western
blotting of Jurkat cells reveals 2 bands of roughly 100 kDa (full length TRIM42) and 50 kDa (unknown protein product). The TRIM42 band is seen at
various levels in all AML samples and faintly in PBMC. No TRIM42 protein is detected in the other human tissues. GAPDH expression (40 kDa) was
used as a loading control. Subcellular fractionation was performed on AML blasts and isolated healthy donor granulocytes (4E). The fractions are
labeled C, cytosolic; N, nuclear; M, membrane; Sk, cytoskeletal. No TRIM42 protein is observed in granulocytes, but the same bands seen in the Jurkat
cell positive control are detected in the N and Sk fractions of the AML blasts. The allele frequencies and genotypes for rs9876490, the T4A associated
cSNP, in the original ethnic populations used by the International HapMap Project (CEU, HCB, JPT, YRI) are shown (4F). The T4A recipient phenotypes
(and frequencies in the CEU population) are AC (0.450) or CC (0.133), and the donor genotype is AA (0.417). The predicted gIR+ in an unrelated
transplant scenario can be calculated: P(AA) 6P(AC + CC) and applied over a range of allele frequencies yielding the MUD SCT curve (4G). When
parental genotypes are considered in the MRD SCT setting (Supplement 1) a similar curve with generally lower gIR+ frequency at each donor allele
frequency is generated (4F). In the case of rs9876490 the T4A gIR+ frequency observed in our cohort (N) fits the predicted MRD SCT curve well.
doi:10.1371/journal.pone.0023217.g004
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23217HapMap Project [22], and its allele frequencies for European
(CEU), Han Chinese (HCB), Japanese (JPT), and Yoruban,
Nigerian (YRI) populations are given in Figure 4F. The population
in our study was 90% European in ancestry (CEU). The T4A
peptide is encoded by the recipient allele, rs9876490_C, and in the
CEU population, it is present at a frequency of 0.358. The gIR
donor genotype, AA, is present in 41.7% with the rs9876490_A
allele being present at a frequency of 0.642. Using Hardy-
Weinberg equilibrium, the frequencies of the gIR donor (AA) and
gIR recipient (AC, CC) genotypes can be calculated. We
generated gIR+ frequency curves for a range of donor allele
frequencies in both an unrelated and related SCT (Figure S1, and
Figure 4G). These curves show the maximum frequency of gIR+
in an unrelated donor setting being 0.25 if the donor genotype (e.g. AA)
exists at frequency 0.5 and the recipient genotype (AC, CC) exist
at a combined frequency of 0.5. This situation occurs with a donor
allele frequency (e.g. A) < 0.7. From the rs9876490 genotype
frequencies given in Figure 4F the predicted gIR in an unrelated(
transplant is 0.243, which is close to the maximum frequency
predicted. The analysis for a matched related donor transplant is
complicated by the fact that not all parental genotypes e.g. father is
CC genotype and mother is AA genotype) can yield sibling
offspring with the possibility of having both donor and recipient
genotypes (Figure S1). Taking these factors into account, the
MRD curve in Figure 4G+ is generated. The maximum gIR
frequency is predicted to occur at a donor allele frequency of 0.632
and yield a gIR+ frequency of 0.174. The frequency of a T4A
gIR+ in our patient cohort is 0.158 (plotted as the filled circle on
Figure 4G) in good agreement with our calculations.
Evidence of T4A-specific cytokine secretion in post-SCT
PBMC
Additional cells from the patient characterized in Figure 3C
were available so we tested T4A’s ability to induce cytokine
secretion in this patient and in a rs9876490 heterozygous healthy
control. After incubating patient and healthy donor PBMC with
T4A-pulsed T2 cells we measured IFN-c and TNF-a secretion
using Luminex analysis. Cytokine secretion is normalized to
maximal cytokine secretion elicited by OKT3 antibody
(Figure 5A). This patient sample had a T4A specific TNF-a
response primarily, and there was a non-statistically significant
increase in IFN-c secretion in response to T4A also. The relatively
modest cytokine responses may in part be a reflection of the small
number of T4A-specific CD8+ cells identified in this patient. IFN-
c and TNF-a secretion were not significantly higher in response to
T4A in the healthy donor.
Because the above assay did not evaluate functional responses to
a target cell that could endogenously produce T4A we performed
tetramer-cytokine flow cytometry on two additional post-SCT
patients. We first generated HLA-A0201 expressing, Epstein-Barr
virus immortalized, lymphoblastic cell lines (EBV-LCLs) that
would serve as the source of endogenous T4A peptides. After the
lines were established we genotyped each line for the rs9876490
cSNP. We identified one EBV-LCL line as heterozygous for
rs9876490 so it could theoretically present the T4A peptide, and
another EBV-LCL line was homozygous for rs9876490_A (i.e. the
donor genotype) so it could not present T4A (Figure 5B). We then
confirmed that both cell lines produced equivalent amounts of
TRIM42 protein by western blot (Figure 5C). We identified 5
frozen PBMC samples that had been obtained $3 months post-
SCT from 4 patients, not receiving systemic steroids at the time of
PBMC collection (2 from 1 patient and 1 each from the other 3
patients), who were T4A gIR+. Each sample was split with K
being incubated with T4A+ EBV-LCL and the other K incubated
with T4A- EBV-LCL. After incubation, we performed tetramer-
cytokine flow cytometry on the samples. Two samples were too
lymphopenic to evaluate, but the 3 evaluable samples are shown
(Figure 5D). In both evaluable patients we observed an increased
number of tetramer+, IFN-c+ CD8+ T cells in the 9 months post-
SCT samples that had been incubated with the T4A+ EBV-LCLs.
T4A mismatch and clinical outcomes
Previous investigations have assessed specific mHA mismatches
in effecting differences in survival [3,19,20]. Because our discovery
method was intended to identify high prevalence candidate minor
antigens, primarily dependent upon gIR frequency, that are
associated with a clinical outcome, in this pilot study cIR, we
tested our cohort to see if T4A gIR+ SCT vs. T4A gIR- SCT were
associated with survival or relapse differences. All 9 patients in our
cohort who were identified as T4A gIR+ had the T4A gIR+
mismatch in the GvL/GvHD direction (i.e. donor homozygous
and recipient heterozygous), not the ‘‘intolerant’’ (i.e. donor
homozygous and recipient homozygous for the other allele)
direction so our analysis was able to evaluate T4A gIR+ in the
GvL/GvHD direction without confounding from possible T4A
reactions in the rejection direction. In our cohort we observed
improved overall (median OS: Not Reached, NR, vs. 26 mos,
P=0.3132) and disease free (median DFS: NR vs. 8 mos,
P=0.1223) survival in the T4A gIR+ cohort; however, neither
outcome met statistical significance primarily because of our
limited sample size. (Figure 6A, 6B). We also observed a non-
statistically significant trend towards improved relapse rate
(Figure 6C) in the T4A+ vs. T4A- cohorts (11% vs. 46%,
P=0.0911). There were no statistically significant differences in
the T4A gIR+ and T4A gIR- cohorts with respect to age, disease,
disease stage, frequency of gender-mismatch transplant, and CMV
incidence (data not shown). Five of the 9 T4A gIR+ patients did
not have $ grade 2 aGvHD or extensive cGvHD, suggesting that
T4A gIR+ is unlikely to be a strong independent mediator of
GvHD.
Discussion
The importance of mHAs in mediating GvL and GvHD in the
allo-HSCT setting has been known for roughly 20 years [2,4].
Traditional T cell cloning, used to identify these potentially
important immune targets have yielded relatively few mHA over
this time frame. One of the main limitations of this approach is
Figure 5. T4A-specific cytokine secretion in post-SCT patient samples. T2 cells were pulsed with T4A peptide and incubated with a
rs9876490 heterozygous control and a T4A gIR+ post-SCT sample. IFN-c and TNF-a secretion were measured by Luminex analysis and normalized to
maximum secretion induced by incubation with OKT3. The T4A gIR+ post-SCT sample had a greater TNF-a (P=0.0083) secretion and a non-
statistically greater IFN-c secretion (student t-test, P=0.3296) when incubated with pulsed T2 cells vs. non-pulsed T2 cells (5A). This difference was
not observed in the healthy control sample (5A). Two HLA-A0201 expressing EBV-LCL lines were generated and genotyped using Sanger sequencing.
One EBV-LCL line was heterozygous for rs9876490 and therefore capable of generating T4A (T4A+), and the other was homozygous for rs9876490_A
and therefore incapable of generating T4A (T4A2) (5B). Both EBV-LCL lines produce full length TRIM42 (5C). Two T4A gIR+ patients were identified
and post-SCT PBMC samples were split and then incubated with both EBV-LCLs. In both patients an increased T4A/tetramer+, IFN-c+ population was
identified in the sample that was incubated with the T4A+ EBV-LCLs and not the T4A- EBV-LCLs (5D).
doi:10.1371/journal.pone.0023217.g005
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until after the T cell is cloned. As a result, significant resources can
be used generating a T cell clone and characterizing its cognate
mHA that, eventually, may not be a good candidate for
therapeutic considerations [5,12,13,18]. One possible method to
address this limitation is to use genomics and bioinformatics
filtering strategies to prioritize candidate mHA for discovery. This
paper describes one approach to this strategy: combining genetic
prevalence data with clinical outcomes and bioinformatics to rank
possible mHA with subsequent confirmation in patient samples.
Our screen is primarily based upon prioritizing candidate mHA
based upon their predicted frequency in a population. This
preliminary ranking is based upon gIR, and candidate mHA could
theoretically be ranked based purely upon donor allele frequencies
and their resultant gIR (see Figure 4G), Figure S1. Using gIR as
the sole criteria for cSNP ranking would have yielded 6,102 cSNPs
having gIR+ $0.2 and 2,301 cSNPs having gIR+ $0.243 – equal
to T4A’s predicted gIR. This number of cSNPs and possible mHA
is prohibitively large for detailed characterization so to further
refine our mHA selection we used Fisher’s exact test to associate a
clinical outcome, cIR, with the measured gIR in out patient cohort
(Figure 1). This approach enabled us to simplify our search for
common mHA that were most closely associated with a clinical
outcome. By using this approach with subsequent bioinformatics
filtering we were able to identify a high prevalence mHA in 3 post-
SCT patients using very small numbers of reagents – 23 ordered
peptides and 5 synthesized tetramers.
Because our method theoretically screened 528,846 (13,91762
alleles619 possible decameric and nonameric peptides containing
the allele) candidate HLA-A2 restricted epitopes represented by
13,917 cSNPs on the Illumina NS-12 array, this analysis does
encounter the problem of multiple testing. If we were to test
13,917 independent cSNPs for a specific outcome (e.g. cIR), the
most conservative test for statistical significance would be to divide
our pre-defined threshold for statistical significance (e.g. P,0.05)
by 13,917, which would yield a P-value < 3610
26. Our method
cannot achieve this level of statistical power for several reasons. In
addition to our limited cohort size, which will obviously hinder
statistical power, our method of using Fisher’s exact test to
measure the association between gIR and cIR yields relatively high
P-values because in the matched related setting there are only
predicted to be, at most, 17% gIR+ donor/recipient pairs. More
importantly, clinical outcomes, including cIR status, are depen-
dent upon many well-established clinical variables, such as age,
disease and its associated prognostic factors (e.g. cytogenetics), and
disease status at transplant. Under the most optimistic circum-
stance, where no gIR+ donor/recipient pair have a clinical
outcome of cIR-, we estimate a sample size of roughly 300 being
needed to achieve P,3610
26, and given the many other clinical
risk factors for cIR- outcomes, to fully assess the association
between a cSNP encoded mHA and cIR would require
significantly more samples than we have available at this time.
Because of these sample size considerations, we used our
combined clinical and genomic ranking data with a bioinformatic
and an in-vitro testing method to refine our list of candidate
peptides to a manageable number, 40, for testing in post-SCT
patient samples.
While our study purports to use both a statistical analysis of
genomic and clinical outcomes with refinement through bioinfor-
matics methods to discover common clinically useful mHA, the
relative utility of gIR, cIR and bioinformatics processing are not
entirely clear. gIR data simply allow ranking by probability of
genetic minor antigen mismatches, and cIR data are susceptible to
multiple clinical covariates and sample size limitations. To
investigate the utility of using both gIR and cIR data (Figure 1C)
to initially prioritize cSNPs, we performed simulations where
donor/recipient pairs were randomly moved between cIR
outcome groups. We performed 3 such simulations and observed
that our original clinical data possessed the most cSNPs with low
P-values (i.e.,0.0375) compared to any of the other random
Figure 6. T4A gIR+ and clinical outcomes. A Kaplan-Meier survival
analysis for the effect of T4A gIR on OS and DFS was performed on the
57 examined patients. A trend towards improved OS (median OS: NR vs.
26 mos, P=0.3132) and DFS (median DFS: NR vs. 8 mos, P=0.1223) was
observed in the T4A gIR+ patients compared to T4A gIR- patients (6A,
6B). Also, a trend towards improved relapse rates was observed in the
T4A gIR+ patients (11% vs. 46%, P=0.0911).
doi:10.1371/journal.pone.0023217.g006
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cSNPs based upon association between gIR and cIR is better than
random chance and supports our view that combining cIR data to
microarray based gIR results is unlikely to reduce mHA predictive
power and can help in the initial prioritizing of candidate mHA
that should be taken on for further testing. The fact that our simple
bioinformatics approach eliminated 16 of the original candidate
cSNPs before any testing, and the IEDB algorithm successfully
predicted the 5 HLA-A0201 binding peptides and rejected the
other 18 ordered peptides, point to the power that the follow-up
bioinformatics approach had in reducing the number of peptides
that need to be ordered and tested in these type of antigen
discovery projects.
T4A is a high gIR+ frequency (predicted MUD gIR+ =0.243,
measured MRD gIR+ =0.158)) mHA that strongly associated
with our defined clinical outcome, cIR, which focuses on immune-
mediated outcomes such as remission, relapse, and GvHD, our
primary interest, and minimizes the impact of non-immune
specific outcomes such as treatment related mortality from
conditioning regimens and infectious complications which could
have affected other clinical metrics such as OS and DFS. Our T4A
survival analysis provides evidence that the cIR composite
outcome reflects some information regarding OS, DFS, and
relapse; however, our method can be easily modified to test cSNP
gIR correlations with other clinical outcomes such as long-term
remission without GvHD, development of GvHD or even OS.
While the T4A gIR+ frequencies are close to the maximum
predicted for a cSNP, our patient sample size prevents us from
drawing definitive conclusions about T4A gIR+ effect on survival
and relapse outcomes. A power calculation for a two-sided test with
a type 1 error rate of 0.05 and a power of 80% to detect a median
survival improvement of 50% would require the T4A gIR+ cohort
to have 96 subjects. Because T4A gIR+ should occur in 17% of our
MRDpatients wewouldneeda totalof565subjects(96predictedto
be T4A gIR+ and 469 predicted to be T4A gIR-), numbers that are
not available except through cooperative groups.
Our study did not identify several of the previously well-
characterized mHAs; however, this is likely because we used an
off-the-shelf microarray and a ranking method that penalizes
cSNPs with low allele frequencies. Both the HA-1 and HA-2
cSNPs are not included in the Illumina NS-12 chip so we cannot
evaluate them in this analysis. One illustrative example however is
the mHA LB-ADIR-1F. This mHA is associated with the cSNP
rs2296377. The cSNP has high minor allele, T, frequency
(MAF=0.213), and this allele is the mHA encoding the recipient
peptide. Consequently the C allele is the donor allele, and it has an
allele frequency of 0.787 [12,14]. This distribution is close to the
ideal distribution of having a donor allele frequency of 0.7. As
expected, we observed many, i.e. 11, LB-ADIR-1F gIR+ in the 57
patient test cohort; however, 2 of the 11 LB-ADIR-1F gIR+ were
identified in the cIR- cohort. This distribution gave a P-value of
P=0.705. If all 11 LB-ADIR-1F gIR were associated with the cIR
cohort the P-value would have been 0.048 similar to the P-value
for T4A, which had all gIR+ associated with cIR+. These
dramatic changes are a result of our relatively small sample size
and would be mitigated if a larger cohort of patients were
examined.
This study demonstrates how using genomics data combined
with clinical outcomes and bioinformatics pipelines can guide
mHA discovery so that common mHAs with desirable clinical
properties can be preferentially selected for further evaluation as
possible prognostic [3,19,20] or therapeutic targets [5]. Each
individual test that we employed can be readily optimized.
Microarray analysis is becoming less expensive, and through
genome imputation methods [33] data for all of the high frequency
cSNPs annotated through the 1000 Genomes Project can be
encompassed. Clinical data and outcomes will be more accurate as
larger SCT populations are followed for longer periods of times.
Finally, bioinformatics will allow increasingly accurate epitope
prediction algorithms [34] to more accurately predict epitopes for
testing and also enable further filtering of candidate cSNPs
according to features such as tissue expression.
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